Enumeral is enabling and accelerating the discovery and development of novel antibody immunotherapies, or immunomodulators, which are validated with our human-driven immune profiling platform. The core technology behind our platform was developed at and licensed from the Massachusetts Institute of Technology, Harvard University, Whitehead Institute for Biomedical Research and Massachusetts General Hospital.
Our antibodies are rapidly generated directly from the platform using proprietary cellular libraries derived from target-specific immunized sources or from human patient donors.
We perform sensitive measurements on single immune cells using our proprietary technology in order to mine the immune system’s rich collection of cells for information that is difficult to obtain using other methods and that may guide the development of effective therapeutics and diagnostics. The efficiency and sensitivity provided through our platform increases the probability of finding rare antibody-secreting cells associated with disease or drug response, as well as rare and previously unknown antibodies that may have the characteristics essential to becoming safe and effective drugs.
Studying rare immune cells obtained directly from human patients for their functional responses can potentially lead to selection of best-in-class antibody drug candidates that may have a higher likelihood of successful development. Such knowledge generated from our platform is also being applied to better understand which drug candidates might work in which patients, and, at what stage of disease.
Our current antibody discovery and development programs target the checkpoint proteins PD-1, OX40 and Lag3.